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overestimate GFR. The assessment of ascites in the 
RFHC poses a problem given that it is a subjective 
measure.
One pitfall for both equations is that a marker 
for muscle mass estimation was not incorporated. 
Decreased muscle mass has a great impact on over-
estimation of kidney function, especially in male 
patients with cirrhosis, as shown in a recent study.(4)
Even though, as stated by the researchers, the 
GRAIL model is skewed to predict lower GFR, it 
would be interesting to see how this equation would 
have compared to the RFHC. Further validation 
studies are required for both formulas; however, we 
are finally on the path to conceive a better GFR for-
mula in the population with cirrhosis.
Joana Carvão, M.D. 
Luís Jasmins, M.D.
Gastroenterology Department
Hospital Central do Funchal
Funchal, Portugal
REFERENCES
1) Asrani SK, Jennings LW, Trotter JF, Levitsky J, Nadim MK, 
Kim WR, et al. A model for glomerular filtration rate assessment 
in liver disease (GRAIL) in the presence of renal dysfunction. 
H 2019;69:1219-1230.
2) Kalafateli M, Wickham F, Burniston M, Cholongitas E, 
Theocharidou E, Garcovich M, et al. Development and validation 
of a mathematical equation to estimate glomerular filtration rate 
in cirrhosis: the royal free hospital cirrhosis glomerular filtration 
rate. H 2017;65:582-591.
TO THE EDITOR:
Renal dysfunction is common in liver cirrhosis, and 
it is associated with poor prognosis. However, we still 
have major limitations when assessing renal function 
in patients with cirrhosis. Current available methods 
are biased and have a tendency to consistently overes-
timate glomerular filtration rates (GFRs).
We read with great interest the article by Asrani 
et al.(1) regarding the development of a GFR model in 
patients with liver disease, before and after liver trans-
plant (LT), the glomerular filtration rate assessment in 
liver disease (GRAIL).
Indeed, the need for a new mathematical formula 
for GFR in cirrhosis is of concern. Kalafateli et al. 
also developed a formula, the Royal Free Hospital 
Cirrhosis (RFHC) for estimation of GFR in stable 
patients being evaluated for liver transplantation.(2)
The RFHC comprises age, sex, creatinine, urea, 
international normalized ratio, and ascites whereas 
GRAIL is based on sex, age, ethnicity, creatinine,
blood urea nitrogen, and albumin. There are some 
important differences between the two. First, 
GRAIL comprises ethnicity, a well-known factor 
that affects GFR estimation in the general popula-
tion.(3) Even though these data are well established
in the general population, the effect in the popula-
tion with cirrhosis is still unknown. The RFHC did
not include ethnicity, mostly because of type 2 error. 
Serum albumin levels in GRAIL can be altered 
because of recent albumin infusions and therefore
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REPLY:
We appreciate the interest in our work. Drs. Carvao 
and Jasmins highlight several important points.
First, serum creatinine, sodium, and estimated glo-
merular filtration rate (eGFR) are all imperfect sur-
rogates of renal function in patients with cirrhosis. 
This is especially true in patients with decompen-
sated liver disease, whereby the influence of extrahe-
patic factors may impede accurate estimation. Often, 
renal function is dependent on where the patient 
lies on the acute kidney injury/chronic kidney dis-
ease continuum, the degree of liver dysfunction, and 
other relevant patient characteristics. Developing an 
estimating equation for each and every subset of cir-
rhosis is untenable. One also assumes steady state in 
predictive models, but manipulation or alterations 
are possible across the breadth of current glomeru-
lar filtration rate (GFR) estimating equations. This 
includes changes in relevant parameters with diuresis 
(serum creatinine, serum sodium), changes with use 
of anticoagulation or nutrition (prothrombin time), 
changes with volume management (albumin, degree 
of ascites), changes with muscle mass (gender), or 
assessment of whether serum creatinine is reflective 
of acute kidney injury or chronic kidney disease or a 
combination thereof. Notwithstanding these factors, 
there is a need to include objective measures in pre-
dictive models.
In our study, the use of glomerular filtration rate 
assessment in liver disease (GRAIL) to identify low 
GFR may be helpful for clinically relevant decisions 
before and after transplantation.(1) Although a direct 
comparison was not carried out with the royal free 
hospital equation, the addition of ascites or serum 
sodium did not improve performance characteristics. 
The addition of ascites had marginal improvement 
in bias (eGFr–GFR 6.7 mL/min/1.73 m2 with asci-
tes versus 7.1 mL/min/1.73 m2), but the differences 
were not clinically significant and the need to have 
an objective set allowed us to further remove it from 
model building. In a subsequent study, replacing serum 
creatinine with GRAIL (as compared with other esti-
mates of GFR) in the Model for End-Stage Liver 
Disease ascites–sodium score improved the prediction 
of wait-list mortality, especially for women and those 
with the highest disease severity.(2)
Second, measured GFR remains important. There 
is a need to identify specific scenarios whereby esti-
mating equations may not be enough: The clinician 
may be forced to instead obtain measured GFR, how-
ever onerous or expensive.(3)
Finally, accurate estimation of renal function in the 
future may rely on combining factors that capture sep-
arate surrogates of renal structure and function, as well 
as take the clinical context into consideration. Given 
the pervasive and dynamic effect of renal dysfunction 
in patients with liver disease, and coupled with the 
increasing burden of cirrhosis worldwide, continued 
refinement of current models is warranted.
Sumeet K. Asrani, M.D., M.Sc.
Baylor University Medical Center
Dallas, TX
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